1. Clinical performance evaluation of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays for routine screening of first-time blood donor samples at a French blood donation center
- Author
-
J. Relave, M. Klinkicht, C. Maugard, and C. Fabra
- Subjects
HBsAg ,Clinical Biochemistry ,Human immunodeficiency virus (HIV) ,Blood Donors ,HIV Infections ,medicine.disease_cause ,Roche Diagnostics ,Sensitivity and Specificity ,Antigen ,medicine ,Humans ,Syphilis ,Hepatitis B Surface Antigens ,biology ,business.industry ,Biochemistry (medical) ,Hematology ,Hepatitis C ,Assay sensitivity ,Hepatitis B ,medicine.disease ,Virology ,biology.protein ,Antibody ,business - Abstract
Objectives Implementing fully automated analyzers has become a crucial safety step in blood donation centers. The Elecsys® assays were evaluated on the cobas e 801 module (Roche Diagnostics) for routine first-time blood donor screening. Materials & Methods Five Elecsys infectious disease assays were tested on the cobas e 801 module at Etablissement Francais du Sang, Montpellier, France (March–April 2018). The performance of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays was compared with PRISM HIV O Plus, HCV, HBsAg, HBcore, and newbio pk TPHA assays (specificity analyses)/ARCHITECT Syphilis TP (sensitivity analyses), respectively. Specificity was determined in residual fresh serum samples from unselected first-time blood donors (n ≥ 5195 per parameter). Elecsys assay sensitivity was tested using 30 preselected, positively characterized samples per assay and compared with archived routine testing data for comparator assays. Results Across all parameters, specificities for repeatedly reactive samples ranged from 99.81–100.00% for Elecsys assays and 99.71–99.98% for comparator assays. Sensitivities of Elecsys and comparator assays were the same for hepatitis C (85.19%), hepatitis B surface antigen (70.00%), hepatitis B core antigen antibodies (100.00%), and syphilis (100.00%). The sensitivity of the Elecsys HIV Duo assay was higher than the comparator assay (83.33% vs. 76.67%), but the difference was not statistically significant. Conclusions Elecsys infectious disease assays on the cobas e 801 module demonstrated high specificity and sensitivity for screening first-time blood donor samples, and were comparable with other commercially available assays. The Elecsys assays are reliable tests for screening blood donations.
- Published
- 2022